HU200926B - Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules - Google Patents

Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules Download PDF

Info

Publication number: HU200926B
Authority: HU; Hungary
Prior art keywords: weight; parts; piroxicam; tablets; capsules
Prior art date: 1988-10-28

Application number

HU885621A

Other languages

English (en)

Hungarian (hu)

Other versions

HUT51143A (en

Inventor

Pal Fekete

Denes Bezzegh

Istvan Simonyi

Laszlone Maroshelyi

Jozsefne Zukovics

Janos Tombor

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-28

Filing date

1988-10-28

Publication date

1990-09-28

1988-10-28 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

1988-10-28 Priority to HU885621A priority Critical patent/HU200926B/hu

1989-10-19 Priority to JP1270514A priority patent/JPH02172918A/ja

1989-10-27 Priority to IT22164A priority patent/IT1239542B/it

1989-10-27 Priority to FR8914117A priority patent/FR2638357B1/fr

1989-10-27 Priority to AT0247489A priority patent/AT399277B/de

1989-10-27 Priority to CA002001673A priority patent/CA2001673C/en

1989-10-27 Priority to IL9213889A priority patent/IL92138A/en

1989-10-27 Priority to GB8924286A priority patent/GB2224207B/en

1989-10-30 Priority to DE3936112A priority patent/DE3936112C2/de

1990-04-28 Publication of HUT51143A publication Critical patent/HUT51143A/hu

1990-09-28 Publication of HU200926B publication Critical patent/HU200926B/hu

Links

239000002775 capsule Substances 0.000 title claims abstract description 33
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 26
229960002702 piroxicam Drugs 0.000 title claims abstract description 19
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 title claims abstract description 13
239000008101 lactose Substances 0.000 title claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 title 1
239000000203 mixture Substances 0.000 claims abstract description 27
239000004480 active ingredient Substances 0.000 claims abstract description 16
239000002245 particle Substances 0.000 claims abstract description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
235000019359 magnesium stearate Nutrition 0.000 claims description 12
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
229930195725 Mannitol Natural products 0.000 claims description 11
239000000594 mannitol Substances 0.000 claims description 11
235000010355 mannitol Nutrition 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
238000004090 dissolution Methods 0.000 claims description 10
229920002261 Corn starch Polymers 0.000 claims description 8
239000000843 powder Substances 0.000 claims description 8
239000008120 corn starch Substances 0.000 claims description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
229910052681 coesite Inorganic materials 0.000 claims description 6
229910052906 cristobalite Inorganic materials 0.000 claims description 6
239000006185 dispersion Substances 0.000 claims description 6
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
229910052682 stishovite Inorganic materials 0.000 claims description 6
229910052905 tridymite Inorganic materials 0.000 claims description 6
239000011148 porous material Substances 0.000 claims description 5
239000000377 silicon dioxide Substances 0.000 claims description 5
229910002016 Aerosil® 200 Inorganic materials 0.000 claims description 4
239000007963 capsule composition Substances 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
239000007916 tablet composition Substances 0.000 claims description 4
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 2
239000004094 surface-active agent Substances 0.000 claims description 2
229920002472 Starch Polymers 0.000 claims 1
239000008107 starch Substances 0.000 claims 1
235000019698 starch Nutrition 0.000 claims 1
239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 description 9
229940099112 cornstarch Drugs 0.000 description 6
238000000265 homogenisation Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
229940057950 sodium laureth sulfate Drugs 0.000 description 3
SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 3
FVTSYHPRVGNAQI-UHFFFAOYSA-N 2-aminoethanol;4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-yl-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound NCCO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 FVTSYHPRVGNAQI-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
235000019739 Dicalciumphosphate Nutrition 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
229940038472 dicalcium phosphate Drugs 0.000 description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
229910000906 Bronze Inorganic materials 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229910004298 SiO 2 Inorganic materials 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000010974 bronze Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
239000013078 crystal Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000003825 pressing Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

HU885621A 1988-10-28 1988-10-28 Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules HU200926B (en)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
HU885621A HU200926B (en)	1988-10-28	1988-10-28	Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
JP1270514A JPH02172918A (ja)	1988-10-28	1989-10-19	Ｎ―（２―ピリジル）―２―メチル―４―ヒドロキシ―２ｈ―１，２―ベンゾチアジン―３―カルボオキサミド―１，１―ジオキシドを含む薬剤及びその製造方法
IT22164A IT1239542B (it)	1988-10-28	1989-10-27	Composizione farmaceutica comprendente piroxicam e procedimento per lasua preparazione
FR8914117A FR2638357B1 (fr)	1988-10-28	1989-10-27	Composition pharmaceutique comprenant du piroxicam et son procede de preparation
AT0247489A AT399277B (de)	1988-10-28	1989-10-27	Festes pharmazeutisches piroxicam-präparat und verfahren zu seiner herstellung
CA002001673A CA2001673C (en)	1988-10-28	1989-10-27	Pharmaceutical composition containing piroxicam
IL9213889A IL92138A (en)	1988-10-28	1989-10-27	Pharmaceutical preparations containing pyroxacam and their preparation
GB8924286A GB2224207B (en)	1988-10-28	1989-10-27	Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
DE3936112A DE3936112C2 (de)	1988-10-28	1989-10-30	Arzneimittelpräparate, die Piroxicam enthalten und Verfahren zu deren Herstellung

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU885621A HU200926B (en)	1988-10-28	1988-10-28	Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules

Publications (2)

Publication Number	Publication Date
HUT51143A HUT51143A (en)	1990-04-28
HU200926B true HU200926B (en)	1990-09-28

Family

ID=10970484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU885621A HU200926B (en)	1988-10-28	1988-10-28	Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules

Country Status (9)

Country	Link
JP (1)	JPH02172918A (de)
AT (1)	AT399277B (de)
CA (1)	CA2001673C (de)
DE (1)	DE3936112C2 (de)
FR (1)	FR2638357B1 (de)
GB (1)	GB2224207B (de)
HU (1)	HU200926B (de)
IL (1)	IL92138A (de)
IT (1)	IT1239542B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
JP2964195B2 (ja) *	1992-04-28	1999-10-18	エスエス製薬株式会社	ピロキシカム錠及びその製造法
DE19603402A1 (de) *	1995-02-24	1996-08-29	Basf Ag	Weichgelatinekapseln
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
PT914818E (pt)	1996-06-14	2005-08-31	Kyowa Hakko Kogyo Kk	Comprimido de desintegracao rapida por via intraoral
WO1999052491A1 (en) *	1998-04-08	1999-10-21	Kyowa Hakko Kogyo Co., Ltd.	Tablet manufacturing method and tablet
JP2000095674A (ja)	1998-09-22	2000-04-04	Sato Pharmaceutical Co Ltd	口腔内崩壊時間短縮化錠剤の製造方法及び装置
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
US20060018959A1 (en) *	2002-12-16	2006-01-26	Kissei Pharmaceutical Co. Ltd.	Solid drug for oral use
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
WO2006047493A2 (en)	2004-10-21	2006-05-04	Eurand Pharmaceuticals Limited	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
AU2006273378B2 (en) *	2005-07-25	2011-10-13	Otsuka Pharmaceutical Co., Ltd.	Oral preparation useful in measuring capacity to metabolize pyridine
SG10201407965XA (en)	2009-12-02	2015-02-27	Aptalis Pharma Ltd	Fexofenadine microcapsules and compositions containing them
JP6352188B2 (ja)	2012-08-20	2018-07-04	大塚製薬株式会社	糖代謝能の測定方法及びそれに使用する組成物
KR20210014204A (ko)	2013-03-15	2021-02-08	오츠카 세이야쿠 가부시키가이샤	지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3591584A (en) *	1968-08-27	1971-07-06	Pfizer	Benzothiazine dioxides
GB1308533A (en) *	1969-06-02	1973-02-21	Pfizer	Benzothiazine dioxides as anti-thombotic agents
JPS55129221A (en) *	1979-03-29	1980-10-06	Kaken Pharmaceut Co Ltd	Preparation of oral preparation containing hardly soluble medicine
US4350689A (en) *	1980-02-15	1982-09-21	American Cyanamid Company	Combinations of agents which give enhanced anti-inflammatory activity
US4434164A (en) *	1981-06-01	1984-02-28	Pfizer Inc.	Crystalline benzothiazine dioxide salts
RO88420A (ro) *	1983-04-25	1986-01-30	Pfizer Inc,Us	Procedeu pentru prepararea unor saruri bazice de piroxican depuse pe suporturi farmaceutice
DE3419128A1 (de) *	1984-05-23	1985-11-28	Bayer Ag, 5090 Leverkusen	Dihydropyridinpraeparate und verfahren zu ihrer herstellung
CH663899A5 (fr) *	1985-03-20	1988-01-29	Nestle Sa	Procede pour la preparation d'une composition a base d'un principe actif de faible hydrosolubilite finement divise.
ES545221A0 (es) *	1985-07-02	1986-01-01	Ferrer Int	Procedimiento de obtencion de particulas de 4-hidroxi-2-me- til-n-2-piridil-2h-1,2-benzotiazina-3-carboxamida-1,1-dioxi-do(piroxicam) recubiertas

1988
- 1988-10-28 HU HU885621A patent/HU200926B/hu unknown
1989
- 1989-10-19 JP JP1270514A patent/JPH02172918A/ja active Pending
- 1989-10-27 AT AT0247489A patent/AT399277B/de not_active IP Right Cessation
- 1989-10-27 GB GB8924286A patent/GB2224207B/en not_active Expired - Lifetime
- 1989-10-27 IT IT22164A patent/IT1239542B/it active IP Right Grant
- 1989-10-27 CA CA002001673A patent/CA2001673C/en not_active Expired - Fee Related
- 1989-10-27 FR FR8914117A patent/FR2638357B1/fr not_active Expired - Fee Related
- 1989-10-27 IL IL9213889A patent/IL92138A/en not_active IP Right Cessation
- 1989-10-30 DE DE3936112A patent/DE3936112C2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2001673A1 (en)	1990-04-28
IT8922164A1 (it)	1991-04-27
IT1239542B (it)	1993-11-05
IL92138A (en)	1994-08-26
FR2638357B1 (fr)	1993-10-22
AT399277B (de)	1995-04-25
GB2224207B (en)	1992-06-10
GB2224207A (en)	1990-05-02
DE3936112C2 (de)	1999-02-18
CA2001673C (en)	1996-08-27
DE3936112A1 (de)	1990-05-31
GB8924286D0 (en)	1989-12-13
FR2638357A1 (fr)	1990-05-04
IL92138A0 (en)	1990-07-12
IT8922164A0 (it)	1989-10-27
HUT51143A (en)	1990-04-28
JPH02172918A (ja)	1990-07-04
ATA247489A (de)	1994-09-15

Legal Events

Date

Code

Title

Description

2006-06-28

HC9A

Change of name, address

Owner name: EGIS GYOGYSZERGYAR NYRT., HU

Free format text: FORMER OWNER(S): EGIS GYOGYSZERGYAR, HU

Publication	Publication Date	Title
US6596311B1 (en)	2003-07-22	Fast disintegrating tablets
CA2563440C (en)	2012-11-27	Orally disintegrating tablets and methods of manufacture
DE60121570T2 (de)	2007-07-05	Oral anzuwendende schnell zerfallende feste darreichungsformen
PL206595B1 (pl)	2010-08-31	Preparat farmaceutyczny w postaci mikrosfer, sposób wytwarzania tego preparatu oraz farmaceutyczna postać dawkowania zawierająca ten preparat
US9278063B2 (en)	2016-03-08	Press-coated orally-disintegrating tablets
JPWO2009084678A1 (ja)	2011-05-19	口腔内崩壊錠およびその製造方法
CA2001673C (en)	1996-08-27	Pharmaceutical composition containing piroxicam
DE102004008804A1 (de)	2005-09-08	Mehrschichttablette
HUP0002316A2 (hu)	2002-11-28	Gyorsan olvadó orális adagolási formák
WO2010035282A1 (en)	2010-04-01	Pharmaceutical compositions comprising deferasirox
KR20110052731A (ko)	2011-05-18	의약 고형 제제
JPH02164824A (ja)	1990-06-25	分散性製剤
EP3003277B1 (de)	2019-02-20	Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit rivaroxaban
US6413541B1 (en)	2002-07-02	Disintegrating tablet in oral cavity and production thereof
CZ303694B6 (cs)	2013-03-20	Prípravek nesteroidního protizánetlivého léciva obsahující granulární a extragranulární kompozici a zpusob jeho prípravy
JP2013533881A (ja)	2013-08-29	バノキセリンを含有する医薬組成物
US6365196B1 (en)	2002-04-02	Controlled release solid dosage forms of lithium carbonate
JP2011246428A (ja)	2011-12-08	口腔内崩壊型医薬品及びその製造方法
EP2387993B1 (de)	2012-11-07	Im Mund zerfallende Zolmitriptan-Tabletten und Herstellungsverfahren dafür
US20180344648A1 (en)	2018-12-06	Clobazam tablet formulation and process for its preparation
EP3511001B1 (de)	2021-09-22	Pirfenidonhaltige tablette und kapselformulierung
JP2021167306A (ja)	2021-10-21	崩壊性粒子の製造方法
JP2005112861A (ja)	2005-04-28	口腔内速崩壊錠
JPWO2017064814A1 (ja)	2017-10-19	ジエノゲスト含有錠剤
EP1689371A2 (de)	2006-08-16	Pharmazeutische zusammensetzung mirtazapine enthaltend